Mendus AB Interim Report January – March 2026
Start of clinical program in chronic myeloid leukemia
As part of its updated clinical strategy communicated end of 2025, Mendus is expanding clinical development of the lead product vididencel to include chronic myeloid leukemia (CML). Enrollment of the first patient in the VITAL-CML trial marked the start of clinical development in CML. In parallel, Mendus started a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI), a leading Australian cancer research institute, to support the DIVA trial in acute myeloid leukemia (AML). The trial will commence in the summer and assess vididencel in combination with less intensive induction therapy, further consolidating the position of vididencel as a post-remission immunotherapy.
Erik Manting, Ph.D.
Chief Executive Officer
Significant events of Q1 2026
- Net sales for the period amounted to KSEK - (-)
- Result for the period amounted to KSEK –21,022 (-30,482)
- Earnings and diluted earnings per share totaled to SEK –0.34 (-0.61)
- Mendus entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), a leading Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in AML (acute myeloid leukemia).
- Mendus requested drawdown of SEK 30 million under the loan facility totaling SEK 50 million entered into with Fenja Capital II A/S in November 2025. Furthermore, the company's board of directors resolved, pursuant to the authorization from an extraordinary general meeting in December 2025, and in accordance with the terms and conditions of the loan facility, on a directed issue of 1,935,605 warrants of series 2025/2030 to Fenja.
Significant events after end of reporting period
- Mendus announced an Mendus announced start of clinical program in CML (chronic myeloid leukemia). The company has completed preparations and received all regulatory approvals for the VITAL-CML trial, marking the start of clinical development with the company’s lead product vididencel CML.
- Mendus announced that the first patient has been enrolled in the VITAL-CML trial, which evaluates vididencel in chronic phase CML patients with a sub-optimal response to currently approved tyrosine kinase inhibitors (TKIs).
Financial summary
| 2026 | 2025 | 2025 | |
| Amounts in KSEK | Jan-Mar | Jan-Mar | Jan-Dec |
| Revenue | – | – | – |
| Operating profit/loss | -20,095 | -30,222 | -113,491 |
| Net profit/loss | -21,022 | -30,482 | -113,258 |
| Earnings/loss per share, before and after dilution (SEK) | -0.34 | -0.61 | -2.17 |
| Cash | 74,128 | 84,730 | 64,656 |
| Shareholders equity | 565,137 | 614,539 | 585,065 |
| Number of employees | 19 | 28 | 19 |
The full report is attached as PDF and is available on the company’s website: https://mendus.com/investors/financial-reports/
Webcast investor call, May 8 at 14.00 CEST
The company will host a live presentation and business update today at 14:00 CEST. The presentation will be held in English and includes a Q&A session.
If you wish to participate via webcast please use the link below. Via the audiocast you are able to ask written questions.
https://mendus.events.inderes.com/q1-report-2026/register
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/mendus/q1-report-2026/dial-in